Maia Biotechnology
 |
Maia Biotechnology is a public, Texas based, immune-oncology company.[1]
Company[edit]
It is led by CEO/Chairman Vlad Vitoc, MD, MBA and Chief Scientific Officer Sergei M. Gryaznov, PhD. In August 2022, the company's initial funding round closed, raising $10M.[2] In March 2024, the company's equity fell below .5 M, cause for delisting from NYSE.[3] In April 2024 the company announced the completion of a $1M private placement.[4]
Drug candidates[edit]
THIO (6-thio-2’-deoxyguanosine) is a drug that attempts to kill cells that express telomerase, which is found in 85% of human cancers.[1]
Clinical trials[edit]
Phase II THIO-101[edit]
A phase II THIO-101 clinical trial of THIO sequenced with cemiplimab to treat advanced non-small cell lung cancer (NSCLC). The trial is a multicentre, open-label, dose-finding trial designed to assess anti-tumour activity followed by PD-L1 inhibition. The study population was patients with advanced NSCLC who did not respond or developed resistance to first-line treatments using another checkpoint inhibitor. The trial's primary objectives are to assess tolerability, safety, and clinical efficacy using overall response rate (ORR) as the primary endpoint.[5]
See also[edit]
References[edit]
- ^ a b Wang, Brian (2024-06-05). "Promising Possible Universal Cancer Treatment". NextBigFuture. Retrieved 2024-06-11.
- ^ Cornall, Jim (2022-08-02). "MAIA Biotechnology raises $10M from public offering". Labiotech.eu. Retrieved 2024-06-11.
- ^ "MAIA Biotechnology at Risk of NYSE Delisting Over Equity Shortfalls - TipRanks.com". TipRanks Financial. Retrieved 2024-06-11.
- ^ "MAIA Biotechnology Announces $1.00 Million Private Placement". BioSpace. Retrieved 2024-06-11.
- ^ Priyan, Vishnu (2024-03-07). "MAIA Biotechnology reports positive data from NSCLC therapy trial". Clinical Trials Arena. Retrieved 2024-06-11.